PRTA PROTHENA CORP PUBLIC LTD CO

8-K Current Report

Filed: February 27, 2026

Health Care

Pharmaceutical Preparations

PROTHENA CORP PUBLIC LTD CO (PRTA) 8-K current report filed with SEC EDGAR on February 27, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events

AI Filing Analysis
8-K

Item 7.01 · Regulation FD Disclosure

• Share repurchase program authorized up to $100.0M of outstanding ordinary shares (par value $0.01/share)
• Buyback signals management confidence in valuation at current price levels — typically bullish signal for existing shareholders

+1 more insights

Item 8.01 · Other Events

• Share repurchase plan authorized up to $100M of ordinary shares ($0.01 par value), expiring Dec 31, 2026
• Plan is discretionary — no obligation to repurchase any shares, can be suspended or discontinued at any time

+1 more insights

Get deeper insights on PROTHENA CORP PUBLIC LTD CO

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.